Treatment planning optimisation based on imaging tumour proliferation and cell density

References

• Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000; 47: 551–60
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Chao KS. Current imaging paradigms in radiation oncology. Radiat Res 2005; 163: 1–25
   PubMedGoogle Scholar
• Wintz H. Die Einzeitbestrahlung. Strahlentherapie 1937; 58: 521–7
   Google Scholar
• Thames HD, Hendry JH. Fractionation in radiotherapy. Taylor & Francis, London 1987
   Google Scholar
• Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131–46
   PubMed Web of Science ®Google Scholar
• Begg AC, Hofland I. Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry. Cytometry 1991; 12: 445–54
   PubMedGoogle Scholar
• Toma-Daşu I, Daşu A, Brahme A. Quantifying tumour hypoxia by PET imaging-a theoretical analysis. Adv Exp Med Biol 2008 ( in press).
   Google Scholar
• Kellerer AM, Rossi HH. The theory of dual radiation action. Curr Top Radiat Res Q 1972; 8: 85–158
   Google Scholar
• Chadwick KH, Leenhouts HP. A molecular theory of cell survival. Phys Med Biol 1973; 18: 78–87
   PubMed Web of Science ®Google Scholar
• Douglas BG, Fowler JF. Fractionation schedules and a quadratic dose-effect relationship. Br J Radiol 1975; 48: 502–4
   PubMed Web of Science ®Google Scholar
• Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981–97
   PubMed Web of Science ®Google Scholar
• Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679–94
   PubMed Web of Science ®Google Scholar
• Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2002; 54: 215–28
   PubMed Web of Science ®Google Scholar
• Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, van der Kogel AJ. Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat Res 2006; 165: 326–36
   PubMed Web of Science ®Google Scholar
• Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990; 19: 219–35
   PubMed Web of Science ®Google Scholar
• Fowler JF. Optimum overall times II: Extended modelling for head and neck radiotherapy. Clin Oncol 2008; 20: 113–26
   PubMed Web of Science ®Google Scholar
• Brahme A, Ågren AK. Optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1987; 26: 377–85
   PubMed Web of Science ®Google Scholar
• Begg AC. Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol 1994; 65: 103–8
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449–65
   PubMed Web of Science ®Google Scholar
• Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S–93S
   PubMed Web of Science ®Google Scholar
• Gregoire V. Is there any future in radiotherapy planning without the use of PET: Unraveling the myth. Radiother Oncol 2004; 73: 261–3
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 129–36
   PubMed Web of Science ®Google Scholar
• Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44: 1426–31
   PubMed Web of Science ®Google Scholar
• Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52: 1602–6
   PubMed Web of Science ®Google Scholar
• Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334–6
   PubMed Web of Science ®Google Scholar
• Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells. Nucl Med Biol 2001; 28: 117–22
   PubMed Web of Science ®Google Scholar
• Sun A, Sörensen J, Karlsson M, Turesson I, Langström B, Nilsson P, et al. 1-[11C]-acetate PET imaging in head and neck cancer–a comparison with 18F-FDG-PET: Implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 2007; 34: 651–7
   PubMedGoogle Scholar
• Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999; 22: 210–4
   PubMed Web of Science ®Google Scholar
• Ribom D, Engler H, Blomquist E, Smits A. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 2002; 29: 632–40
   PubMed Web of Science ®Google Scholar
• Nafe R, Herminghaus S, Raab P, Wagner S, Pilatus U, Schneider B, et al. Preoperative proton-MR spectroscopy of gliomas–correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol 2003; 63: 233–45
   PubMed Web of Science ®Google Scholar
• McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg 2007; 106: 660–6
   PubMed Web of Science ®Google Scholar
• Guillevin R, Menuel C, Duffau H, Kujas M, Capelle L, Aubert A, et al. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 2008; 87: 181–7
   PubMedGoogle Scholar
• Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003; 2: 581–7
   PubMed Web of Science ®Google Scholar
• Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005; 4: 35–42
   PubMedGoogle Scholar
• Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: Correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007; 67: 960–71
   PubMedGoogle Scholar
• Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiother Oncol 1999; 50: 13–23
   PubMed Web of Science ®Google Scholar